Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2021

Schedule of Fair Value And Amortized Cost of Marketable Securities

The fair value and amortized cost of marketable securities by major security type as of March 31, 2021 is as follows:

	As of March 31, 2021
(in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Money market funds	$	86,794	$	—	$	—		$	86,794
Non-U.S. government securities		11,269		—		(4	)		11,265
Corporate debt securities		40,675		—		(35	)		40,640
Asset-backed securities		13,398		—		(4	)		13,394
Commercial paper		31,453		—		—			31,453
Total	$	183,589	$	—	$	(43	)	$	183,546

Classified as:
Cash equivalents								$	86,794
Marketable securities									96,752
Total								$	183,546

Reconciliation of Cash, Cash Equivalents and Restricted Cash

The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the consolidated statements of cash flows is as follows:

	March 31,
(in thousands)	2021		2020
Cash and cash equivalents	$	98,829	$	11,696
Restricted cash, non-current		—		48
Total cash, cash equivalents and restricted cash	$	98,829	$	11,744

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities included the following:

(in thousands)	March 31, 2021		December 31, 2020
Research and development costs	$	2,195	$	2,800
Refundable contract liability		836		836
Compensation and benefit costs		499		1,492
Accrued professional fees		514		2,185
Accrued development milestone		—		1,531
Other		83		162
Total accrued expenses and other current liabilities	$	4,127	$	9,006